Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-04Clinical Trial Update: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
Phase 2 results from a study using donor umbilical cord blood stem cell transplants in patients with hematologic malignancies have been post…
-
CLINICAL_TRIALS trial_result · 2018-11-13Clinical Trial Update: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 [Phase 2]
Phase 2 trial investigating obinutuzumab induction in relapsed/refractory Waldenström macroglobulinemia (OBI-1).
-
CLINICAL_TRIALS trial_result · 2018-07-18Clinical Trial Update: Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors [Phase 1]
This clinical trial update reports the completion of a Phase 1 study of CB-839 (telaglenastat), a glutaminase inhibitor, in hematological tu…
-
CLINICAL_TRIALS trial_result · 2018-07-02Clinical Trial Update: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating a triple regimen of devimistat (CPI-613), bendamustine hydrochloride, and rituximab in relapsed or refractory B-cel…
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating alisertib with or without rituximab in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated; results …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF [Phase 1]
Phase 1 study evaluating mobilization of autologous peripheral blood stem cells using interleukin-2 and GM-CSF; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-12Clinical Trial Update: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers [Phase 3]
Phase 3 trial update on the efficacy and safety of ibrutinib in patients with chronic lymphocytic leukemia and indolent B-cell lymphomas who…
-
CLINICAL_TRIALS trial_result · 2018-04-11Clinical Trial Update: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma [Phase 1]
Phase 1 study evaluating alisertib in combination with vorinostat in adults with relapsed or recurrent Hodgkin lymphoma, B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2018-03-15Clinical Trial Update: A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia [Phase 2]
This is a Phase II clinical trial update for perifosine in relapsed/refractory Waldenström's macroglobulinemia. The trial status is complete…
-
CLINICAL_TRIALS trial_result · 2018-01-26Clinical Trial Update: Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) [Phase 2]
Phase 2 trial evaluating the combination of bortezomib and rituximab in Waldenström's macroglobulinemia has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 [Phase 1, Phase 2]
Extension study update for IMO-8400 in Waldenström's macroglobulinemia following completing a prior study; results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-07-24Clinical Trial Update: Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
This clinical trial update reports Phase 1/Phase 2 results for fludarabine and cyclophosphamide as conditioning therapy for donor stem cell …
-
CLINICAL_TRIALS trial_result · 2017-06-02Clinical Trial Update: Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma [Phase 1, Phase 2]
Clinical trial update reports completed Phase 1 and Phase 2 results for flavopiridol in previously treated chronic lymphocytic leukemia and …
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating rituximab plus dexamethasone in patients with low-grade non-Hodgkin lymphoma, including follicular and marginal zon…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab in patients undergoing donor peripheral blood stem cell transplantation for relapsed or refractory B-cell…
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies [Phase 2, Phase 3]
A phase 2/3 trial evaluating non-myeloablative allogeneic HSCT from HLA-matched related or unrelated donors in low-grade B-cell malignancies…
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia [Phase 2]
A Phase 2 trial evaluating thalidomide, lenalidomide, and rituximab for previously treated Waldenström macroglobulinemia was terminated, wit…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia [Phase 2]
Phase 2 trial update for carfilzomib, rituximab and dexamethasone in Waldenström's macroglobulinemia has completed and results posted.
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia [Phase 2]
Phase 2 study of idelalisib in Waldenström macroglobulinemia was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2016-12-22Clinical Trial Update: A Phase II Study of Doxycycline in Relapsed NHL [Phase 2]
Phase II trial of doxycycline in relapsed non-Hodgkin lymphoma was terminated and results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-11-23Clinical Trial Update: PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia [Phase 1, Phase 2]
Clinical trial update comparing PCD versus RCD regimens for Waldenström's macroglobulinemia in Phase 1/2; current status is not specified.
-
CLINICAL_TRIALS trial_result · 2016-07-25Clinical Trial Update: Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia [Phase 1]
A Phase 1 trial of pomalidomide, dexamethasone, and rituximab in Waldenström's macroglobulinemia was terminated, with results posted in 2016…
-
CLINICAL_TRIALS trial_result · 2016-06-10Clinical Trial Update: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia [Phase 2]
Phase 2 study evaluating ofatumumab with bortezomib in previously untreated Waldenström macroglobulinemia was terminated; results were poste…
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a radiolabeled monoclonal antibody with rituximab, with/without filgrastim and interleukin-11, in relapsed or r…